Amicus Therapeutics (Nasdaq: FOLD) announced it has commenced the U.S. registration Phase 3 trial with its investigational drug, Amigal(TM) (migalastat hydrochloride) for the treatment of Fabry disease. The Company has reached agreement with the …
Read the full story »A focus on disease-specific efforts by pharmaceutical and biotech companies
Read in depth analysis by industry experts on investing opportunities and business strategies
Learn about corporate strategies, positioning and investing opportunities
Stay on top of the industry with our industry news bulletin
Diversify to hedge your investment during economic turbulence
Unless points of contention between the pharmaceutical industry and the medical profession are resolved satisfactorily, future advances in the quality of patient care may be put at risk. This is the conclusion reached by a …
Harvard Medical School plans to fortify its conflict-of-interest rules for physicians and researchers, the Boston Globe reports. The move comes amid a U.S.
InterMune, Inc. (Nasdaq: ITMN) announced results from the two Phase 3 CAPACITY studies evaluating pirfenidone in patients with idiopathic pulmonary fibrosis (IPF). The primary endpoint of change in percent predicted Forced …
Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that its collaborators at the University of Pennsylvania have opened a Phase 1 clinical trial to evaluate SB-728-T for the treatment of HIV/AIDS. Based on …
Advanced Cell Technology, Inc. (OTC Pink Sheets: ACTC) and its collaborators reported that human oocytes (or ‘eggs’) have the capacity to extensively reprogram adult human cells. The research, which appears online ahead of print in …
Axentis Pharma AG is to present its recent successes in developing and financing a new therapeutic formulation for treating chronic lung disease at the 2nd Annual European Life Science CEO Forum in Zurich, Switzerland. This …
Pharmaceutical companies are tapping into online social networking sites such as Facebook and MySpace and using new media forms to reach wider Australian audiences. Writing in the latest edition of Australian Prescriber, health …
Risks associated with one of the most commonly prescribed drugs in Australia, accounting for about one million prescriptions a year, are examined in two articles in the latest Medical Journal of Australia. …
Novartis and Medicines for Malaria Venture (MMV) announced the launch of Coartem® Dispersible, a new pediatric formulation of Coartem® (artemether/lumefantrine 20 mg/120 mg), for the treatment of uncomplicated malaria in infants and children.
In a new study, Cymbalta (duloxetine HCl) 60-120 mg, taken once daily, reduced pain severity significantly, compared with placebo, in patients with osteoarthritis pain of the knee. Data from the 13-week randomized, double-blind, placebo-controlled clinical …
The oncology drug treatment landscape is in the midst of change, according to Cutting Edge Information’s latest market forecast report “Oncology Roadmap: Brand Spending Benchmarks and …
British pharmaceutical giant GlaxoSmithKline says it will shutter its Philadelphia headquarters and operate out of North Carolina.
TRENTON, N.J. (AP) — British drugmaker GlaxoSmithKline PLC is restructuring its U.S. operations, starting with reducing its U.S. sales …
Merck Serono, the division for innovative pharmaceuticals of Merck KGaA, Darmstadt, Germany, today held a cornerstone ceremony at the Merck Serono Biotech Center (MSBC), its production site in Corsier-sur-Vevey, Switzerland, to mark the expansion of …
The US Food and Drug Administration (FDA) has approved a 30-minute onset of action for Focalin(R) XR (dexmethylphenidate HCl) extended-release capsules for the treatment of Attention Deficit/Hyperactivity Disorder (ADHD), bringing potential benefits for young patients …
Portola Pharmaceuticals, a biopharmaceutical company developing innovative drugs that provide significant advances in cardiovascular and inflammatory diseases, and cancer, announced new clinical data that demonstrate PRT060128, the Company’s novel anti-platelet drug that directly and reversibly …
ViroPharma Incorporated (Nasdaq: VPHM) announced the presentation of data from its ongoing, open-label study, showing that in this study Cinryze(TM) C1 inhibitor therapy successfully treated all types of acute hereditary angioedema (HAE) attacks seen in …
Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced positive results from a Phase 1a clinical trial of MBX-2982. A summary of …
Raptor Pharmaceuticals Corp. (”Raptor” or the “Company”) (OTC Bulletin Board: RPTP), announced positive results in its Phase IIa study of oral 4-methylpyrazole (”4-MP”) in subjects with ALDH2 deficiency, or ethanol intolerance, as the initial development …
Potentia Pharmaceuticals, a privately held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), presented Phase I data last week during the Retina Subspecialty Day at the American Academy of Ophthalmology (AAO) …
| NASDAQ | 2236.20 | ||
| S&P 500 | 1104.18 |
| M | T | W | T | F | S | S |
|---|---|---|---|---|---|---|
| « Jun | ||||||
| 1 | 2 | 3 | 4 | 5 | ||
| 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| 13 | 14 | 15 | 16 | 17 | 18 | 19 |
| 20 | 21 | 22 | 23 | 24 | 25 | 26 |
| 27 | 28 | 29 | 30 | |||
